Reported 6 days ago
Wall Street analysts are bullish on Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company focusing on innovative cancer treatments, despite its stock being down 74% over the past year and hovering near its 52-week low of under $4. With optimistic price targets averaging $19.54, Iovance's FDA-approved therapy, Amtagvi, shows promise, especially in capturing a vast melanoma patient market. Although challenges exist, including manufacturing costs and potential regulatory hurdles, cautious investors may find Iovance a worthwhile addition to their portfolios.
Source: YAHOO